Compare AMRX & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | FCN |
|---|---|---|
| Founded | 2002 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.6B |
| IPO Year | 2018 | 1996 |
| Metric | AMRX | FCN |
|---|---|---|
| Price | $17.94 | $155.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $15.60 | ★ $165.00 |
| AVG Volume (30 Days) | ★ 1.8M | 409.2K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.89 | 5.51 |
| EPS | 0.37 | ★ 3.89 |
| Revenue | N/A | ★ $3,788,857,000.00 |
| Revenue This Year | $4.48 | $7.39 |
| Revenue Next Year | $7.13 | $7.10 |
| P/E Ratio | $48.95 | ★ $39.53 |
| Revenue Growth | N/A | ★ 2.44 |
| 52 Week Low | $9.20 | $137.65 |
| 52 Week High | $19.26 | $189.30 |
| Indicator | AMRX | FCN |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 49.28 |
| Support Level | $16.61 | $153.47 |
| Resistance Level | $18.13 | $166.98 |
| Average True Range (ATR) | 0.67 | 4.41 |
| MACD | -0.09 | -0.23 |
| Stochastic Oscillator | 48.32 | 36.99 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.